Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Immunotherapy
Researchers from Asahikawa Medical College, Department of Pathology publish findings in immunotherapy
May 6th, 2009
Scientists discuss in 'Focal adhesion kinase as an immunotherapeutic target' new findings in immunotherapy. According to recent research from Asahikawa, Japan, "Focal adhesion kinase (FAK) is a ubiquitously expressed non-receptor tyrosine kinase involved in cancer progression and metastasis that is found overexpressed in a large number of tumors such as breast, colon, prostate, melanoma, head and neck, lung and ovary. Thus, FAK could be an attractive tumor associated antigen (TAA) for developing immunotherapy against a broad type of malignancies." "In this study, we determined whether predicted T cell epitopes from FAK would be able to induce anti-tumor immune cellular...
Source: Vaccine Weekly (2009-05-06)
|
